of between I and 2 i1WmL at all four stages of the routine screening procedure. This level of sensitivity was also attained using the manufacturer's recommended silver nitrate confirmation procedure. By concentrating the sample onto two discs instead of one, little extra cost is incurred with the latter confirmation test, with no apparent loss of sensitivity.
Although there have been reports of false positives for morphine': 3 with the haemagglutination test (BCL, Lewes, UK) we have experienced incidences of false negatives, and what could be described as lack of sensitivity to opiates at concentrations in excess of the lower levels of sensitivity quoted by the manufacturers. The problem was first noticed when some samples giving strong positive results for morphine on a routine Toxi-Lab screen were found to be negative with the haemagglutination test. An independent laboratory confirmed these results. The problem recurred with another batch of tubes a short time later. The manfacturcrs did eventually admit that there was a problem, and, after a considerable time delay, replaced the faulty batches free of charge.
In the absence of RIA or EMIT methods for opiates in our laboratory, and because of the unreliability of the haemagglutination test we now perform glucuronide hydrolysis on all samples from possible heroin addicts. Although extra costs arc incurred, we suggest that hydrolysis of the sample followed by a Toxi-Lab screen and/or silver nitrate confirmation test should always be carried out if morphine/heroin abuse is suspected. The author replies as follows:
S SLIM, P BARNES and L ALLEN
In spite of the results of Slim et 01 in finding morphine at 1-2 I1g mL-1 at all four stages of the Toxi-Lab procedure it is still our view that we need to use a more sensitive method, as well as the TLC procedure, for the detection of morphine. We regard Toxi-Lab as an excellent procedure for differentiating between different drugs, and opiates in particular, but we now also use an EMIT technique routinely when we look for morphine.
ALASTAIR HAY Department of Chemical Pathology.
Old Medical School. London LS2 9JT. UK Do serum fructosamine levels accurately ret1ect levels of glycated albumin? I am not convinced that serum glycated albumin (GSA) is poorly correlated with serum fructosamine levels as indicated in the article by Winocour et al. I My main concern is that they express GSA levels as percentage of albumin and compare these against fructosamine levels which are expressed in concentrations units. Moreover, in their unit for GSA, albumin concentration is implicitly incorporated, whilst in the fructosamine unit albumin concentration is not taken into account. This can confound a correlation, especially if one takes into consideration that samples with so-called albumin levels that fall within the reference range (for our laboratory 35-55 giL) can mean a variation in albumin levels of up to 57%. To apply this to a GSA level of 6% can produce a calculated concentration value of 2·1 giL for GSA in a specimen with an albumin concentration of 35 giL or of 3 giL if the albumin level was 50 giL. This difference is quite significant! Accordingly, the authors have not shown the real correlation between GSA and fructosamine for their data and it would be unwise to speculate on the possible difference between these two measurements of long-term diabetic control using their results as presented. The author replies as follows:
Dr Kuyl is mistaken in his concern for the effect of albumin concentration on levels of glycated serum albumin (GSA) and serum fructosamine. Our method of estimating GSAI involved measuring total albumin level by immunoturbidimetry in the original sample and relating it to the combined albumin content in the bound and unbound fractions.
Serum fructosamine is an indirect measure of glyeated albumin with nearly 80% being attributed to albumin." The need for correction for albumin concentration has not been clearly established. It would seem that albumin concentrations above 35 giL do not influence serum fructosamine values.
. 4
Others have, however, argued for routine correction for different albumin concentrations." 7 In patients with altered plasma protein turnover, both corrected and uncorrected serum fructosamine values or indeed any other measure of glycated albumin will not be a true reflection of diabetic control.
In our cross-sectioned study all subjects had albumin concentrations within the normal range and none had conditions leading to abnormal plasma protein turnover. On the above evidence we believe the correlation between GSA and serum fructosamine is valid. In a series of 17patients with anorexia nervosa, the median serum concentration of 25-hydroxycholecalciIerol (25-0HD) was 8 nmoUL(range: <5-48 nmol/L): this was significantly lower (P«).(X)2) than the
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corresponding values in healthy control subjects (median: 38; range: 13-59 nmoUL). Serum 25-0HO concentrations were subnormal in 15 (88%) of our patients. Serum 1.25-dihydroxycholecalciferol (1.25-OHD) concentrations were low in only two anorexic patients, and the median serum concentration of this metabolite did not differ significantly from that in control subjects. The median serum PTH and plasma calcium and phosphate concentrations in patients with anorexia nervosa were not significantly different from those in controls.
In contrast, seven patients with bulimia (whose body weight was significantly greater than that of the anorexic patients) had median 25-0HO, 1,25-0HO and PTH concentrations that did not differ significantly from those in controls.
Clearly, therefore, hypovitaminosis 0, without clinically evident osteomalacia, is common in patients with anorexia ncrvosa, at least in the UK where diminished sunlight exposure may exacerbate any dietary deficiency. Serum 25-0HD concentrations were not found to be abnormal in anorexics investigated in the USA. I We would also like to comment on the observation by Mira et al. that 13 out of 90 patients with eating disorders had abnormal serum magnesium levels although the mean serum magnesium concentration did not differ significantly from control values. Recognition of oceasional hypomagnesaemia in these patients is clinically relevant since this abnormality may cause refractory cardiac failure, myopathy, and other electrolyte disturbances."
Mira et al. did not report any raised plasma creatinine concentrations in their patients, whereas we reported levels above the normal range in seven out of 10 anorexic patients when this variable was corrected for body weight;" none of our patients had abnormal plasma creatinine concentrations when the uncorrected values were considered.
Lastly. we would like to comment on the suggestion by Mira et al. that the raised plasma cholesterol concentrations may contribute to an increased risk of cardiovascular disease. In this context, it is relevant that we have reported platelet hyperaggregability and enhanced release of thromboxane A2 (a vasoconstrictor and stimulator of platelet aggregation) in patients with anorexia nervosa." We have also suggested that these altered platelet responses may contribute to the pathogenesis of the reported diminished peripheral and renal perfusion in anorexic patients.
